• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在前列腺特异性膜抗原(PSMA)扫描分期中区分生理性输尿管摄取与受累淋巴结:对放射治疗计划的影响。

Distinguishing Physiological Ureter Uptake From an Involved Lymph Node in Staging Prostate-Specific Membrane Antigen (PSMA) Scans: Implications for Radiation Planning.

作者信息

Ching Lauren, Bourne Matthew, Kearney Tim, Choudhury Karbi, Zwart Alan L, Danner Malika T, Suy Simeng, Esposito Giuseppe, Collins Sean

机构信息

Radiation Oncology, MedStar Georgetown University Hospital, Washington, DC, USA.

Radiology, MedStar Georgetown University Hospital, Washington, DC, USA.

出版信息

Cureus. 2024 Jun 25;16(6):e63105. doi: 10.7759/cureus.63105. eCollection 2024 Jun.

DOI:10.7759/cureus.63105
PMID:39055460
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11271162/
Abstract

Prostate-specific membrane antigen (PSMA) imaging has become a mainstay diagnostic tool in staging unfavorable primary prostate cancer (PC) and identifying sites of recurrence in previously treated PC. One of the biggest pitfalls of PSMA imaging is rapid radionucleotide excretion in the urine via the​ kidneys, ureters, and bladder.​ The positron-emission tomography (PET) images obtained show increased radiotracer activity in these structures, which can occlude or even mimic true malignant disease. We describe the diagnostic challenges encountered in differentiating benign versus malignant disease with PSMA scans. A 78-year-old male presented ​to our outpatient radiation oncology office ​with high-risk prostate cancer. His medical history was significant for ulcerative colitis (UC). Magnetic resonance imaging (MRI) revealed an enlarged prostate and a Prostate Imaging Reporting and Data System (PI-RADS) class 4 lesion. A subsequent transperineal biopsy confirmed unilateral Gleason 8 adenocarcinoma. A PSMA PET scan was read as increased uptake in the right prostate and a left external iliac node. The patient, having been initially informed of a positive lymph node metastasis, sought a second opinion,​resulting in​​ ​a CT urogram that revealed physiologic ureteral uptake. We were thus able to avoid lymph node radiation and morbidity to the surrounding bowel, already chronically inflamed with ulcerative colitis. This study ​demonstrates the ​potential for misinterpretation of PSMA uptake in the ureter as lymph node metastases. We discuss how peri-uretic activity can hinder accurate visualization of pelvic lymph node metastases. This study highlights the need for careful image interpretation of PSMA uptake patterns in order to avoid diagnostic errors and unnecessary radiation to ​at-risk​​ ​organs in prostate cancer management.

摘要

前列腺特异性膜抗原(PSMA)成像已成为分期高危原发性前列腺癌(PC)和识别既往接受过治疗的PC复发部位的主要诊断工具。PSMA成像最大的缺陷之一是放射性核素通过肾脏、输尿管和膀胱迅速经尿液排出。所获得的正电子发射断层扫描(PET)图像显示这些结构中的放射性示踪剂活性增加,这可能掩盖甚至模拟真正的恶性疾病。我们描述了在通过PSMA扫描鉴别良性与恶性疾病时遇到的诊断挑战。一名78岁男性因高危前列腺癌就诊于我们的门诊放射肿瘤学办公室。他有溃疡性结肠炎(UC)病史。磁共振成像(MRI)显示前列腺增大,前列腺影像报告和数据系统(PI-RADS)分类为4类病变。随后的经会阴活检证实为单侧 Gleason 8级腺癌。PSMA PET扫描显示右侧前列腺和左侧髂外淋巴结摄取增加。该患者最初被告知存在阳性淋巴结转移,遂寻求第二种意见,结果CT尿路造影显示为生理性输尿管摄取。因此,我们能够避免对淋巴结进行放疗以及对周围已因溃疡性结肠炎而长期发炎的肠管造成损伤。这项研究证明了将输尿管中PSMA摄取误判为淋巴结转移的可能性。我们讨论了输尿管周围的活性如何阻碍盆腔淋巴结转移的准确可视化。这项研究强调了在前列腺癌管理中需要仔细解读PSMA摄取模式的图像,以避免诊断错误和对高危器官进行不必要的放疗。

相似文献

1
Distinguishing Physiological Ureter Uptake From an Involved Lymph Node in Staging Prostate-Specific Membrane Antigen (PSMA) Scans: Implications for Radiation Planning.在前列腺特异性膜抗原(PSMA)扫描分期中区分生理性输尿管摄取与受累淋巴结:对放射治疗计划的影响。
Cureus. 2024 Jun 25;16(6):e63105. doi: 10.7759/cureus.63105. eCollection 2024 Jun.
2
More advantages in detecting bone and soft tissue metastases from prostate cancer using F-PSMA PET/CT.使用F-PSMA PET/CT检测前列腺癌骨和软组织转移方面有更多优势。
Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7.
3
Histological comparison between predictive value of preoperative 3-T multiparametric MRI and Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer.术前 3-T 多参数 MRI 和 Ga-PSMA PET/CT 扫描对前列腺癌根治性前列腺切除术和盆腔淋巴结清扫术病理结果的预测价值的组织学比较。
BJU Int. 2021 Jan;127(1):71-79. doi: 10.1111/bju.15134. Epub 2020 Sep 7.
4
Ga-Labeled Prostate-specific Membrane Antigen Ligand Positron Emission Tomography/Computed Tomography for Prostate Cancer: A Systematic Review and Meta-analysis.Ga 标记前列腺特异性膜抗原配体正电子发射断层扫描/计算机断层扫描在前列腺癌中的应用:系统评价和荟萃分析。
Eur Urol Focus. 2018 Sep;4(5):686-693. doi: 10.1016/j.euf.2016.11.002. Epub 2016 Nov 15.
5
Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging Before Radical Prostatectomy: Central Review of Imaging and Comparison with Histopathology of Extended Lymphadenectomy.镓-PSMA-11正电子发射断层扫描/计算机断层扫描用于根治性前列腺切除术前行原发性淋巴结分期:影像学的中心回顾及与扩大淋巴结清扫术组织病理学的比较
Eur Urol Focus. 2021 Mar;7(2):288-293. doi: 10.1016/j.euf.2021.01.004. Epub 2021 Jan 25.
6
Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard.阴性前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描能否避免新诊断前列腺癌患者进行盆腔淋巴结清扫?一项以病理组织学为参考标准的系统评价和Meta分析
Eur Urol Oncol. 2022 Feb;5(1):1-17. doi: 10.1016/j.euo.2021.08.001. Epub 2021 Sep 17.
7
Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters.哪些接受术前前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描检查时存在淋巴结摄取的前列腺癌患者在根治性前列腺切除术后前列腺特异性抗原持续存在的风险更高?通过整合临床、磁共振成像和功能成像参数来确定系统性疾病的指标。
Eur Urol Oncol. 2024 Apr;7(2):231-240. doi: 10.1016/j.euo.2023.08.010. Epub 2023 Sep 9.
8
Incremental Impact of [ Ga]Ga-PSMA-11 PET/CT in Primary N and M Staging of Prostate Cancer Prior to Curative-Intent Surgery: a Prospective Clinical Trial in Comparison with mpMRI.[68Ga]Ga-PSMA-11 PET/CT 对前列腺癌根治性手术前 N 和 M 分期的增量影响:与 mpMRI 比较的前瞻性临床试验。
Mol Imaging Biol. 2022 Feb;24(1):50-59. doi: 10.1007/s11307-021-01650-9. Epub 2021 Sep 14.
9
Lymph node staging with 68Ga-PSMA PET in patients with intermediate and high-risk prostate cancer suitable for radical prostatectomy managed in a prostate cancer unit.在前列腺癌单 位管理的适合接受根治性前列腺切除术的中高危前列腺癌患者中,使用 68Ga-PSMA PET 进行淋巴结分期。
Chin Clin Oncol. 2023 Jun;12(3):22. doi: 10.21037/cco-23-10.
10
Primary lymph-node staging with Ga-PSMA PET in high-risk prostate cancer: pathologic correlation with extended pelvic lymphadenectomy specimens.高危前列腺癌中 Ga-PSMA PET 进行初级淋巴结分期:与扩大盆腔淋巴结清扫标本的病理相关性。
Urol Oncol. 2021 Aug;39(8):494.e1-494.e6. doi: 10.1016/j.urolonc.2020.10.074. Epub 2020 Nov 19.

本文引用的文献

1
Intensity modulated radiation therapy with stereotactic body radiation therapy boost for unfavorable prostate cancer: five-year outcomes.调强放射治疗联合立体定向体部放射治疗对高危前列腺癌的疗效:五年随访结果
Front Oncol. 2023 Nov 23;13:1240939. doi: 10.3389/fonc.2023.1240939. eCollection 2023.
2
Quantitative and Qualitative Assessment of Urinary Activity of F-Flotufolastat-PET/CT in Patients with Prostate Cancer: a Post Hoc Analysis of the LIGHTHOUSE and SPOTLIGHT Studies.F-Flotufolastat-PET/CT 尿活动的定量和定性评估:LIGHTHOUSE 和 SPOTLIGHT 研究的事后分析。
Mol Imaging Biol. 2024 Feb;26(1):53-60. doi: 10.1007/s11307-023-01867-w. Epub 2023 Nov 6.
3
Early biochemical outcomes following neoadjuvant/adjuvant relugolix with stereotactic body radiation therapy for intermediate to high risk prostate cancer.
新辅助/辅助使用relugolix联合立体定向体部放射治疗中高危前列腺癌后的早期生化结果
Front Oncol. 2023 Oct 17;13:1289249. doi: 10.3389/fonc.2023.1289249. eCollection 2023.
4
Prostate Cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology.《前列腺癌(第四版)》,2023 年,NCCN 肿瘤学临床实践指南。
J Natl Compr Canc Netw. 2023 Oct;21(10):1067-1096. doi: 10.6004/jnccn.2023.0050.
5
Patient-reported persistent symptoms after radiotherapy and association with quality of life for prostate cancer survivors.放疗后患者报告的持续性症状及其与前列腺癌幸存者生活质量的关系。
Acta Oncol. 2023 Nov;62(11):1440-1450. doi: 10.1080/0284186X.2023.2259597. Epub 2023 Nov 7.
6
Traditional and novel imaging modalities for advanced prostate cancer: A critical review.晚期前列腺癌的传统与新型成像方式:批判性综述
Urol Ann. 2023 Jul-Sep;15(3):249-255. doi: 10.4103/UA.UA_170_20. Epub 2023 Jul 17.
7
PSMA PET/CT for Primary Staging of Prostate Cancer - An Updated Overview.前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描用于前列腺癌的初始分期——最新综述
Semin Nucl Med. 2024 Jan;54(1):39-45. doi: 10.1053/j.semnuclmed.2023.07.001. Epub 2023 Jul 22.
8
Diagnostic Performance and Safety of Positron Emission Tomography with F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE).F-rhPSMA-7.3 正电子发射断层扫描在初诊不利中高危前列腺癌患者中的诊断性能和安全性:一项 3 期前瞻性多中心研究(LIGHTHOUSE)的结果。
Eur Urol. 2023 Oct;84(4):361-370. doi: 10.1016/j.eururo.2023.06.018. Epub 2023 Jul 5.
9
Diagnostic Performance and Safety of F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT). Reply.F-rhPSMA-7.3正电子发射断层扫描在疑似前列腺癌复发男性中的诊断性能和安全性:一项3期前瞻性多中心研究(SPOTLIGHT)的结果。回复
J Urol. 2023 Sep;210(3):411-412. doi: 10.1097/JU.0000000000003598. Epub 2023 Jun 23.
10
Prostate Cancer-PET Imaging Update.前列腺癌-PET成像的最新进展。
Cancers (Basel). 2023 Jan 28;15(3):796. doi: 10.3390/cancers15030796.